menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Datopotamab Shows Clinical Activity in EGFR-Mutated Lung Cancer

    BUSINESSWIRE

    Merck, Daiichi`s ADC Lung Cancer Trial Shows Promise Despite Deaths

    BUSINESSWIRE

    ENHERTU Shows Activity In HER2+ Breast Cancer With Brain Metastases

    BUSINESSWIRE

    Ifinatamab Deruxtecan Shows Promise In Small Cell Lung Cancer Trial

    BUSINESSWIRE

    First Patient Dosed In IDeate-Lung02 Trial Of Ifinatamab Deruxtecan

    PHARMABIZ

    IDeate-Lung02 Phase 3 Trial Of Ifinatamab Deruxtecan Initiated

    BUSINESSWIRE

    Patritumab Deruxtecan BLA Submission Receives Complete Response Letter From FDA

    BUSINESSWIRE

    Tropion-Lung01: Nsclc Vs Chemo Clinically Meaningful Improvement

    BUSINESSWIRE

    Daiichi Sankyo`s Biologic Enhertu (fam-trastuzumab deruxtecan-nxki) Receives Approval in the U.S.

    FDA

    AstraZeneca, Daiichi aim for first pan-tumor ADC approval

    BIOPHARMADIVE

    ENHERTU granted Priority Review for patients with HER2-positive solid tumors

    BUSINESSWIRE

    Enhertu granted Priority Review in the US for patients with solid tumours

    PRESS RELEASE

    Seagen patent invalidated in long-running Daiichi Sankyo spat

    FIERCE PHARMA

    After Enhertu success, Daiichi and AstraZeneca branch off

    FIERCE BIOTECH

    ENHERTU® Approved in the EU as the First HER2 Directed Therapy for NSCLC

    BUSINESSWIRE

    ENHERTU Demonstrated Survival Across Multiple HER2 Expressing Solid Tumors

    BUSINESSWIRE

    AstraZeneca-Daiichi get some clarity on Enhertu follow up med

    FIERCE BIOTECH

    NICE poised to reject Enhertu in HER2-low breast cancer

    FIERCE PHARMA

    CHMP recommends AstraZeneca, Daiichi`s Enhertu for HER2-mutant NSCLC

    PRESS RELEASE

    ENHERTU Shows Strong Responses in Treated HER2-mutant Advanced Lung Cancer

    BUSINESSWIRE

    BioNTech, DualityBio steer ADC into PhIII with Enhertu

    #N/A

    ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients

    BUSINESSWIRE

    Enhertu wins two FDA breakthrough therapy designations

    PHARMACEUTICAL TECHNOLOGY

    FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan

    ONCLIVE

    Trastuzumab Deruxtecan Approved in Japan for HER2-Mutated Metastatic NSCLC

    ONCLIVE

    Enhertu Shows OS across multiple HER2-expressing advanced solid tumours in PII

    PRESS RELEASE

    Expanding Definitions of HER2 Expression Mediate Role of ADCs in Breast Cancer

    ONCLIVE

    Enhertu gains more Chinese momentum with HER2-low breast cancer approval

    PRESS RELEASE

    Enhertu shows 37.1% response rate in HER2-expressing solid tumours

    BUSINESSWIRE

    Daiichi Sankyo to showcase latest research towards creating new standards care

    PHARMABIZ

    AstraZeneca Pharma India receives DCGI’s approval for import of cancer drug

    THEHINDUBUSINESSLINE

    AZ, Daiichi`s Enhertu posts trial win in numerous cancer types

    FIERCE PHARMA

    ENHERTU Showed Durable Responses Across Multiple HER2-expressing Tumor

    BUSINESSWIRE

    New Ambrx CEO spies a path for ousted breast cancer med

    FIERCE BIOTECH

    Trastuzumab Deruxtecan Garners Approval for HER2+ Metastatic Breast Cancer

    PRESS RELEASE

    Enhertu approved in Europe for HER2-low metastatic breast cancer

    PRESS RELEASE

    ENHERTU Type II Variation Application Validated by EMA for HER2 NSCLC

    BUSINESSWIRE

    Enhertu recommended for approval in EU by CHMP for patients with breast cancer

    PRESS RELEASE

    ENHERTU Approved in the EU for Patients with Previously Treated Gastric Cancer

    BUSINESSWIRE

    Daiichi submits Enhertu sNDA to treat patients with non-small cell lung cancer

    PHARMABIZ

    AstraZeneca exec touts Enhertu`s `game-changing` SABCS showing

    FIERCEPHARMA

    ENHERTU Achieved Overall Survival, Reducing the Risk of Death by 36%

    BUSINESSWIRE

    Enhertu neoadjuvant trial has caveats, Daiichi exec says

    FIERCEPHARMA

    Novartis shows PFS in breast cancer subgroups; AZ reveals Enhertu data

    ENDPTS

    Enhertu granted full approval in Japan

    THEPHARMALETTER

    EMA committee recommends approval of Enhertu for patients

    PHARMABIZ

    Daiichi`s Biologic Enhertu (Trastuzumab Deruxtecan) Receives Approval in the U.S.

    FDA

    Daiichi Sankyo dials up Enhertu projection

    FIERCEPHARMA

    Roche nets FDA approval for HER2-low breast cancer test

    FIERCEBIOTECH

    ENHERTU Continues to Demonstrate Clinically Meaningful Tumor Response

    BUSINESSWIRE

    Daiichi Sankyo Make Bold Strides in Oncology Across DXd ADC Portfolio at ESMO

    BUSINESSWIRE

    ALX & Quantum Leap Collaborative Announce the Selection of Evorpacept

    GLOBENEWSWIRE

    FDA approves second indication for AZ & Daiichi`s Enhertu in less than a week

    PRESS RELEASE

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2

    BUSINESSWIRE

    Guardant Health Receives FDA Approval for Guardant360® CDx as Diagnostic

    BUSINESSWIRE

    Daiichi`s Biologic Enhertu (Trastuzumab Deruxtecan) Receives Approval in U.S.

    FDA

    ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy

    BUSINESSWIRE

    ADC shrinks brain metastases in HER2+ breast cancer patients

    EUROPEAN PHARMACEUTICAL REVIEW

    AstraZeneca and Daiichi Sankyo sprint to market after FDA clears Enhertu

    ENDPTS

    FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

    PRNEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.